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Introduction 
Accurate survival prediction is important for terminally ill patients with 
advanced cancer to avoid unnecessary anti-cancer therapies and provide 
appropriate palliative care [1, 2]. However, it is difficult to predict the 
prognosis in these patients. The Research Network of the European 
Association for Palliative Care identified performance status (PS), cancer 
anorexia-cachexia syndrome, dyspnea, delirium, leukocytosis, lymphopenia, 
and high C-reactive protein as some of the predictors of life expectancy in 
this patient population [2]. Moreover, a number of prognostication tools, 
including the Palliative Prognostic Score (PaP score) [3], the Palliative 
Prognostic Index (PPI) [4], and the Japan Palliative Oncology 
Study-Prognostic Index (JPOS) [5] have been developed to obtain a rapid 
estimate of life expectancy. PPI, which is based on assessment of the 
Palliative Performance Scale (PPS) [6], oral intake, dyspnea at rest, edema 
and delirium, was developed by assessing patients admitted to the palliative 
care unit, and has since been successfully validated in a variety of clinical 
settings, such as acute care hospital and home care settings [7-10]. Although 
it has been pointed out that PPI is inferior to the PaP score and JPOS for 
predicting long-term survival, it has the advantage of being a simple tool for 
predicting short-term survival without blood examinations [5].  
Lung cancer is the leading cause of cancer-related death worldwide, and 
was estimated, as of 2008, to be responsible for 1.38 million deaths annually 
[11]. Therefore, it is important to identify prognostication tools for advanced 
lung cancer patients. Previous studies carried out to evaluate the usefulness 
of PPI, however, patients with lung cancer accounted for only 6.9%-25.8% of 
the study populations [7-10]. Lung cancer can be divided into two categories: 
small cell lung carcinoma (SCLC) and non-small cell lung carcinoma 
(NSCLC); SCLC has a more aggressive disease course than NSCLC [12]. It 
remains unclear whether PPI is equally applicable to lung cancer patients 
with NSCLC and SCLC, who show different clinical courses. We conducted a 
retrospective study to evaluate the usefulness of PPI for short-term survival 
prediction in patients with lung cancer. In addition, we compared the 
usefulness of PPI as a prognostic tool in lung cancer patients with SCLC and 
NSCLC. 
  
Methods 
Patient selection and evaluation 
We retrospectively reviewed the clinical data of patients with lung cancer. 
The inclusion criteria were; 1) patients with cytologically or histologically 
confirmed diagnosis of lung cancer, 2) who were admitted to our hospital to 
receive palliative care, and 3) whose death confirmed between 2009 and 2013. 
The exclusion criteria were; 1) history of anti-cancer therapy, including 
surgery, radical irradiation, brain irradiation, or chemotherapy after 
admission, 2) absence of detection of recurrence after radical surgery or 
radiation therapy, 3) admission to the hospital mainly for acute illnesses 
such as infection, tumor hemorrhage, or adverse effects of treatment, and 4) 
apparent death from other causes than lung cancer. Patients who received 
palliative irradiation were included. 
We determined PPI based on the information recorded in the clinical 
charts at the last admission to our institution. The index was calculated by 
summing the scores assigned for each of the factors of PPS, oral intake, 
dyspnea at rest, edema, and delirium (Table 1). The PPS measures physical 
performance and is measured in 10% decrements, from fully ambulatory and 
healthy (100%) to death (0%) [6]. Clinical information, such as the age, 
gender, histological diagnosis, epidermal growth factor receptor (EGFR) gene 
status, and Eastern Cooperative Oncology Group PS at admission were also 
reviewed. The study was approved by the Ethics Committee of the 
University of Toyama.  
 
Statistical analysis 
Survival curves were drawn by the Kaplan-Meier method. Survival was 
calculated from the date of admission to the date of death. Survival was 
compared by the log-rank test between patients with PPI values of ≤ 6 and 
those with PPI values of > 6. Multivariate analysis was performed using the 
Cox proportional hazards model, with adjustments for the age, gender, 
histological diagnosis, and EGFR gene status. The sensitivity and specificity 
of a PPI of > 6 for predicting death within three weeks was evaluated. In 
addition, we also evaluated the association between PPI and the survival 
time, and the sensitivity and specificity of PPI for predicting the short-term 
survival separately in patients with NSCLC and SCLC.  
  
Results 
The date of death could be confirmed in 165 patients with lung cancer 
between 2009 and 2013. Of these, 49 had received anti-cancer treatment 
after the last admission to our hospital, 24 patients were admitted for acute 
illnesses, 5 patients showed no recurrence after radical surgery or 
chemoradiation therapy, and 3 patients apparently died of causes other than 
lung cancer. Finally, we included the data of 84 patients, including 67 
patients with NSCLC and 17 patients with SCLC.  
Table 2 shows the patient characteristics. The median (range) age was 
72.5 (45-88) years and 74 (88.1%) were male. There were 4, 23, 40 and 17 
patients with a PS of 1, 2, 3 and 4, respectively.  
Figure 1 shows the Kaplan-Meier curve for the two groups divided 
according to the PPI using the cutoff level of 6. The group with a PPI of > 6 
showed a significantly shorter survival time than that with a PPI of ≤ 6 (P < 
0.0001). The sensitivity and specificity of PPI determined using the cutoff 
level of 6 for less than three weeks’ survival were 61.3% and 86.8%, 
respectively. Table 3 shows the association between each of the examined 
variables and the survival as assessed by the Cox proportional hazards 
model. The analysis identified PPI (P < 0.0001) and histological diagnosis (P 
= 0.011) as being independently associated with the patient survival.  
Figure 2 shows the association between PPI and survival in patients with 
NSCLC and SCLC. A significant association was detected in both 
populations, and the sensitivity and specificity of PPI determined using the 
cutoff value of 6 for predicting less than three weeks’ survival were 66.7% 
and 87.0% for patients with NSCLC, and 50.0% and 85.7% for patients with 
SCLC, respectively.  
 
Discussion 
The present study revealed a close association between PPI and survival in 
terminally ill patients with lung cancer, and the association was maintained 
even after the patients were divided into NSCLC and SCLC groups. The 
index showed a high specificity for prediction of less than three weeks’ 
survival, while the sensitivity was relatively low, especially in patients with 
SCLC. 
PPI was first developed by assessment of patients in palliative care units, 
and subsequently, its ability for prognostication was validated in a variety of 
clinical settings [7-10]. The sensitivity of 61.3% determined in the present 
study was consistent with previous reports [7, 9, 10], although it decreased to 
50% when the analysis included only patients with SCLC. The lower 
sensitivity in patients with SCLC likely reflects the aggressive nature of 
SCLC. Some patients with SCLC showed rapid deterioration even if the 
value of PPI on the day of admission was ≤ 6. Arai et al. reported that 
measurement of the change of PPI is useful for predicting the survival in 
patients with advanced cancer [13]. They suggest that it is necessary to not 
only consider the value of PPI at a single time point, but also the disease 
history and change of the general status during the clinical course.  
The present study had several limitations. First, the study included only 
subjects from a single institution, and the sample size was relatively small. 
Therefore, the sample might not have been representative. Second, the 
accuracy of evaluation of the subjective symptoms of dyspnea at rest or 
diagnosis of delirium might have been less than optimal, due to the 
retrospective nature of the study. 
In conclusion, our findings revealed the existence of a close association 
between PPI and survival in patients with lung cancer receiving palliative 
care. However, the index showed a low sensitivity for the prediction of less 
than three weeks’ survival in patients with SCLC, probably due to the 
aggressive nature of this disease. 
  
Figure legends 
Figure 1 Kaplan-Meier curve for lung cancer patients, including both SCLC 
and NSCLC patients, divided according to the PPI at the cutoff level of 6. 
Figure 2 Kaplan-Meier curve for patients with SCLC and NSCLC divided 
according to the PPI at the cutoff level of 6. 
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